Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/23172
Title: Response of S180 murine tumor to bleomycin in combination with radiation and hyperthermia using micronucleus assay: A multimodality approach for therapeutic augmentation
Authors: Rao, B S Satish
Devi, P Uma
Keywords: Bleomycin;Hyperthermia;Micronuclei;Multimodality treatment;Radiation
Issue Date: Jul-2005
Publisher: NISCAIR-CSIR, India
IPC Code: IntCl.7A61P
Abstract: Response of a transplantable tumor, S180, grown intradermally in inbred Balb/c mice, was assessed by using micronucleus assay after treating the solid tumors with bleomycin (BLM), radiation (RT) and hyperthermia (HT) vis-a-vis multimodality approach. The frequency of micronuclei (MN) though did not vary greatly during the one week of observation in untreated tumors, it significantly increased in the drug and RT groups at 24 hr post-treatment. However, MN frequency was non-significant in the HT group from the control. A drug dose dependent linear increase in the frequency of MN induction was evident in 10, 15 and 20 mg/kg body weight BLM alone treated groups. Combination of radiation with BLM or HT further increased the MN counts in the bimodality groups. But, MN induction at 24 hr post-treatment in the trimodality group (BLM+RT +HT) was non-significant from that of the bimodality treatments. However, the tumors treated with trimodality treatment presented severe tumor necrosis, indicating increased cell loss, and resulting in immediate tumor regression. In all the bi-modality groups MN counts though declined 3 or 5 days post-treatment, the values remained significantly higher than the control, on day 7 post-treatment. Micronucleus assay could be used as a predictive parameter for the assessment of post-irradiation tumor regression response. However, the tumor response assessment with MN assay alone may not be sufficient and the role of other parameters, such as apoptosis and necrosis, in immediate tumor regression, especially radiosensitive/thermosensitive tumors can not be ignored while taking multimodality approach into consideration for cancer therapy.
Page(s): 596-600
URI: http://hdl.handle.net/123456789/23172
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.43(07) [July 2005]

Files in This Item:
File Description SizeFormat 
IJEB 43(7) 596-600.pdf1.32 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.